Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia

Journal of Clinical Psychiatry

Volumn 73, Issue 8, 2012, Pages 1077-1086

  Houston, John P ^a,b,f   Kohler, Jared ^c   Bishop, Jeffrey R ^d   Ellingrod, Vicki L ^e   Ostbye, Katherine M ^c   Zhao, Fangyi ^a   Conley, Robert R ^a   Hoffmann, Vicki Poole ^a   Fijal, Bonnie A ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c BioStat Solutions Inc   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f SYNEOS HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; FLUOXETINE PLUS OLANZAPINE; OLANZAPINE; SEROTONIN 2C RECEPTOR;

ANKYRIN REPEAT AND KINASE DOMAIN CONTAINING 1 GENE; ARTICLE; BIPOLAR DISORDER; BORDERLINE STATE; CAUCASIAN; CLINICAL TRIAL (TOPIC); DOPAMINE D2 RECEPTOR GENE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; PRIORITY JOURNAL; SCHIZOPHRENIA; SEROTONIN 2C RECEPTOR GENE; SEX DIFFERENCE; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESISTANT DEPRESSION; WEIGHT GAIN;

EID: 84865743042     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11m06916     Document Type: Article

References (54)

1. Coccurello R, Moles A. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther. 2010;127(3):210-251. doi:10.1016/j. pharmthera.2010.04.08 PubMed
2. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry. 2007;12(8):707-747. doi:10.1038/sj.mp.40209 PubMed
3. Leckband SG, Bishop JR, Ellingrod VL. Pharmacogenomics in psychiatry. J Pharm Pract. 2007;20(3):252-264. doi:10.17/08971907304824
4. Stice E, Spoor S, Bohon C, et al. Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science. 2008;322(5900):449-452. doi:10.126/science.16150 PubMed
5. Correll CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl). 2004;174(4):477-489 [Berl]. doi:10.107/s0213-04-1949-9 PubMed
6. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519-526. doi:10.1038/sj.np.13027 PubMed
7. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet. 2002;359(9323):2086-2087. doi:10.1016/S0140-6736(02)08913-4 PubMed
8. Reynolds GP, Zhang Z, Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry. 2003;160(4):677-679. doi:10.176/api.ajp.160.4.67 PubMed
9. Hong CJ, Liou YJ, Bai YM, et al. Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenet Genomics. 2010;20(6):359-366. doi:10.1097/FPC.0b013e328397d06 PubMed
10. Yuan X, Yamada K, Ishiyama-Shigemoto S, et al. Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia. 2000;43(3):373-376. doi:10.107/s012505056 PubMed
11. Gebhardt S, Theisen FM, Haberhausen M, et al. Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study. J Clin Pharm Ther. 2010;35(2):207-211. doi:10.1/j.1365-2710.209.01084.x PubMed
12. Zyprexa [package insert]. http://pi.lilly.com/us/zyprexa-pi.pdf. Indianapolis; IN: Eli Lilly and Company; 2011.
13. Comuzzie AG, Allison DB. The search for human obesity genes. Science. 1998;280(5368):1374-1377. doi:10.126/science.280.5368.1374 PubMed
14. Sargent PA, Sharpley AL, Williams C, et al. 5-HT2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology (Berl). 1997;133(3):309-312 [Berl]. doi:10.107/s0213050407 PubMed
15. Lappalainen J, Zhang L, Dean M, et al. Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C). Genomics. 1995;27(2):274-279. doi:10.106/geno.195.1042 PubMed
16. Covell NH, Weissman EM, Essock SM. Weight gain with clozapine compared to first generation antipsychotic medications. Schizophr Bull. 2004;30(2):229-240. doi:10.1093/oxfordjournals.schbul.a07074 PubMed
17. Koga M. [Clinical factors related to gains in body mass index (BMI) among patients under long-term antipsychotic treatment]. Seishin Shinkeigaku Zasshi. 2003;105(4):473-488. PubMed
18. Andersen SW, Clemow DB, Corya SA. Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. J Clin Psychiatry. 2005;66(11):1468-1476. doi:10.408/JCP.v6n18 PubMed
19. Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature. 1995;374(6522):542-546. doi:10.1038/374542a0 PubMed
20. Ellingrod VL, Perry PJ, Ringold JC, et al. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet. 2005;134B(1):76-78. doi:10.102/ajmg.b.20169 PubMed
21. Miller DD, Ellingrod VL, Holman TL, et al. Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet. 2005;133B(1):97-100. doi:10.102/ajmg.b.3015 PubMed
22. Templeman LA, Reynolds GP, Arranz B, et al. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics. 2005;15(4):195-200. doi:10.1097/0121301-205040-02 PubMed
23. Godlewska BR, Olajossy-Hilkesberger L, Ciwoniuk M, et al. Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene. Pharmacogenomics J. 2009;9(4):234-241. doi:10.1038/tpj.209.18 PubMed
24. De Luca V, Mueller DJ, de Bartolomeis A, et al. Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol. 2007;10(5):697-704. doi:10.1017/S14614570707547 PubMed
25. Basile VS, Masellis M, De Luca V, et al. -759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet. 2002;360:1790-1791. PubMed Comment on Lancet. 2002;359(9323):2086-2087.
26. Tsai SJ, Hong CJ, Yu YW, et al. -759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet. 2002;360(9347):1790. PubMed Comment on Lancet. 2002;359(9323):2086-2087.
27. Theisen FM, Hinney A, Brömel T, et al. Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapineinduced weight gain among German schizophrenic individuals. Psychiatr Genet. 2004;14(3):139-142. doi:10.1097/0414-204090-03 PubMed
28. Park YM, Cho JH, Kang SG, et al. Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients. J Clin Pharm Ther. 2008;33(1):55-60. doi:10.1/j.1365-2710.208.0872.x PubMed
29. Berridge KC. Food reward: brain substrates of wanting and liking. Neurosci Biobehav Rev. 1996;20(1):1-25. doi:10.1016/0149-7634(95)03-B PubMed
30. Martel P, Fantino M. Mesolimbic dopaminergic system activity as a function of food reward: a microdialysis study. Pharmacol Biochem Behav. 1996;53(1):221-226. doi:10.1016/091-3057(95)0187-5 PubMed
31. Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37(3):177-193. doi:10.2165/0308-1937030-01 PubMed
32. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat. 2004;23(6):540-545. doi:10.102/humu.2039 PubMed
33. Dubertret C, Bardel C, Ramoz N, et al. A genetic schizophrenia- susceptibility region located between the ANKK1 and DRD2 genes. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(3):492-499. doi:10.1016/j.pnpbp. 2010.02.03 PubMed
34. Kidd KK, Morar B, Castiglione CM, et al. A global survey of haplotype frequencies and linkage disequilibrium at the DRD2 locus. Hum Genet. 1998;103(2):211-227. doi:10.107/s0439050809 PubMed
35. Zhang ZJ, Yao ZJ, Zhang XB, et al. No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response. Acta Pharmacol Sin. 2003;24(3):235-240. PubMed
36. Lane HY, Liu YC, Huang CL, et al. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol. 2006;26(2):128-134. doi:10.1097/01.jcp.0203196.65710.2b PubMed
37. Schulz SC, Zanarini MC, Bateman A, et al. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry. 2008;193(6):485-492. doi:10.192/bjp.bp.107.037903 PubMed
38. Zanarini MC, Schulz SC, Detke HC, et al. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2011;72(10):1353- 1362. doi:10.408/JCP.08m04138yel PubMed
39. Tohen M, Vieta E, Goodwin GM, et al. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry. 2008;69(11):1776-1789. doi:10.408/JCP.v69n13 PubMed
40. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007;68(2):224-236. doi:10.408/JCP.v68n0207 PubMed
41. Houston JP, Fijal B, Heinloth AN, et al. Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients. Psychiatry Res. 2010;175(1-2):171-172. doi:10.1016/j.psychres.209.06.014 PubMed
42. Gunes A, Melkersson KI, Scordo MG, et al. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol. 2009;29(1):65-68. doi:10.1097/JCP.0b013e31819302c3 PubMed
43. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263-265. doi:10.1093/bioinformatics/bth457 PubMed
44. Gao X, Starmer J, Martin ER. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet Epidemiol. 2008;32(4):361-369. doi:10.102/gepi.20310 PubMed
45. Mulder H, Franke B, Beek van der- AA, et al. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol. 2007;27(4):338-343. doi:10.1097/JCP. 0b013e3180a76dc0 PubMed
46. Okada M, Northup JK, Ozaki N, et al. Modification of human 5-HT(2C) receptor function by Cys23Ser, an abundant, naturally occurring aminoacid substitution. Mol Psychiatry. 2004;9(1):55-64. doi:10.1038/sj.mp.401357 PubMed
47. Mulder H, Franke B, van derBeek AA, et al. The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study. Pharmacogenomics J. 2007;7(5):318-324. doi:10.1038/sj.tpj.65042 PubMed
48. Risselada AJ, Mulder H, Heerdink ER, et al. The association between serotonin 2C receptor polymorphisms and weight gain and eating behavior in patients using mirtazapine: a prospective follow-up study. J Clin Psychopharmacol. 2010;30(2):207-209. doi:10.1097/JCP.0b013e3181d489d7 PubMed
49. Bah J, Westberg L, Baghaei F, et al. Further exploration of the possible influence of polymorphisms in HTR2C and 5HTT on body weight. Metabolism. 2010;59(8):1156-1163. doi:10.1016/j.metabol.209.1.07 PubMed
50. Kuo DY. Co-administration of dopamine D1 and D2 agonists additively decreases daily food intake, body weight and hypothalamic neuropeptide Y level in rats. J Biomed Sci. 2002;9(2):126-132. PubMed
51. Bina KG, Cincotta AH. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology. 2000;71(1):68-78. doi:10.159/05452 PubMed
52. Wang GJ, Volkow ND, Logan J, et al. Brain dopamine and obesity. Lancet. 2001;357(9253):354-357. doi:10.1016/S0140-6736(0)03643-6 PubMed
53. Lencz T, Robinson DG, Xu K, et al. DRD2 variation and weight gain in first episode schizophrenia [abstract]. Schizophr Bull. 2009;35(suppl 1):107.
54. Houston JP, Dharia S, Bishop JR, et al. Replicated association of single nucleotide polymorphisms in the DRD2 and ANKK1 genes with prolactin increases in olanzapine-treated women. Biol Psych. 2010;67(9 supplement):245S.